Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” Ozempic found outside the authorized drug supply chain. The contents of the ...